| Name | Title | Contact Details |
|---|
Founded by Josh Harris and David Blitzer, with a significant strategic investment by The Chernin Group (TCG), Unrivaled Sports oversees a diverse portfolio of youth sports properties across Baseball, Softball, Football, and Action Sports. Unrivaled Sports portfolio includes Ripken Baseball®, Cooperstown All Star Village, Sports Force Parks™, Baseball Factory™, Softball Factory™, We Are Camp, and the ForeverLawn Sports Complex at the Pro Football Hall of Fame Village. Unrivaled Sports has partnerships in Baseball with Hall of Famer Cal Ripken, Jr., and in Action Sports with 5-time Olympian Shaun White. All its properties are committed to providing young athletes with world-class experiences, development opportunities, and platforms to excel. Learn more at playunrivaled.com.
BNCCORP, Inc. (OTCQB: BNCC), headquartered in Bismarck, N.D., is a registered bank holding company dedicated to providing banking and wealth management services to businesses and consumers in its local markets. The Company operates community banking and wealth management businesses in Arizona, Minnesota and North Dakota. BNC also conducts mortgage banking from locations in the Midwest. The Company offers financial products and services to meet the financial needs of its current customers, and potential customers, in the markets it serves.
Qualitas is a full-service consulting firm dedicated to quality results for our clients. We provide expert advice and technical support for business processes and tools, especially Contract Lifecycle Management (CLM) and Enterprise Legal Management (ELM) solutions. We are passionate about helping our clients achieve long‑lasting success, and we are proud to be a woman-owned business.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.